Amissi Sadiki

Amissi Sadiki

Auto-generated profile, based on publicly available information

Amissi Sadiki

Northeastern University Department of Chemistry and Chemical Biology Boston, MA 02115

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2020 in Antibody Therapeutics
Verified
Journal Article
Open access
PDF file
ASAmissi Sadiki
Amissi Sadiki
SVShefali R Vaidya
Shefali R Vaidya
MAMina Abdollahi
Mina Abdollahi
GBGunjan Bhardwaj
Gunjan Bhardwaj
MDMichael E Dolan
Michael E Dolan
ZZZhaohui Sunny Zhou
Zhaohui Sunny Zhou
Traditionally, non-specific chemical conjugations, such as acylation of amines on lysine or alkylation of thiols on cysteines, are widely used; however, they have several shortcomings. First, the lack of site-specificity results in heterogeneous products and irreproducible processes. Second, potential modifications near the complementarity-determining region may reduce binding affinity and specificity. Conversely, site-specific methods produce well-defined and more homogenous antibody conjugates, ensuring developability and clinical applications. Moreover, several recent side-by-side comparisons of site-specific and stochastic methods have demonstrated that site-specific approaches are more likely to achieve their desired properties and functions, such as increased plasma stability, less variability in dose-dependent studies (particularly at low concentrations), enhanced binding efficiency, as well as increased tumor uptake. Herein, we review several standard and practical site-specific bioconjugation methods for native antibodies, i.e., those without recombinant engineering. First, chemo-enzymatic techniques, namely transglutaminase (TGase)-mediated transamidation of a conserved glutamine residue and glycan remodeling of a conserved asparagine N-glycan (GlyCLICK), both in the Fc region. Second, chemical approaches such as selective reduction of disulfides (ThioBridge) and N-terminal amine modifications. Furthermore, we list site-specific antibody–drug conjugates in clinical trials along with the future perspectives of these site-specific methods.

15 September 2014 in Fuel Cells
Verified
Journal Article
Closed access
PDF file
KTK. Tran
K. Tran
TNT. Q. Nguyen
T. Q. Nguyen
ABA. M. Bartrom
A. M. Bartrom
ASA. Sadiki
A. Sadiki
JHJohn Haan
John Haan

1 September 2014 in Electrochimica Acta
Verified
Journal Article
Closed access
ASAmissi Sadiki
Amissi Sadiki
PVPaul Vo
Paul Vo
SHShouzhen Hu
Shouzhen Hu
TCThomas S. Copenhaver
Thomas S. Copenhaver
LSLouis Scudiero
Louis Scudiero
JHJohn L. Haan
John L. Haan

15 April 2020 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
ASAmissi Sadiki
Amissi Sadiki
EKEric M. Kercher
Eric M. Kercher
HLHaibin Lu
Haibin Lu
RLRyan T. Lang
Ryan T. Lang
BSBryan Q. Spring
Bryan Q. Spring
ZZZhaohui Sunny Zhou
Zhaohui Sunny Zhou

18 March 2024 in Bioconjugate Chemistry
Verified
Journal Article
Open access
ASAmissi Sadiki
Amissi Sadiki
SLShanshan Liu
Shanshan Liu
SVShefali R. Vaidya
Shefali R. Vaidya
EKEric M. Kercher
Eric M. Kercher
RLRyan T. Lang
Ryan T. Lang
ZZZhaohui Sunny Zhou
Zhaohui Sunny Zhou
A versatile chemo-enzymatic tool to site-specifically modify native (nonengineered) antibodies is using transglutaminase (TGase, E.C. 2.3.2.13). With various amines as cosubstrates, this enzyme converts the unsubstituted side chain amide of glutamine (Gln or Q) in peptides and proteins into substituted amides (i.e., conjugates). A pleasant surprise is that only a single conserved glutamine (Gln295) in the Fc region of IgG is modified by microbial TGase (mTGase, EC 2.3.2.13), thereby providing a highly specific and generally applicable conjugation method. However, prior to the transamidation (access to the glutamine residue by mTGase), the steric hindrance from the nearby conserved N-glycan (Asn297 in IgG1) must be reduced. In previous approaches, amidase (PNGase F, EC 3.5.1.52) was used to completely remove the N-glycan. However, PNGase F also converts a net neutral asparagine (Asn297) to a negatively charged aspartic acid (Asp297). This charge alteration may markedly change the structure, function, and immunogenicity of an IgG antibody. In contrast, in our new method presented herein, the N-glycan is trimmed by an endoglycosidase (EndoS2, EC 3.2.1.96), hence retaining both the core N-acetylglucosamine (GlcNAc) moiety and the neutral asparaginyl amide. The trimmed glycan also reduces or abolishes Fc receptor-mediated functions, which results in better imaging agents by decreasing nonspecific binding to other cells (e.g., immune cells). Moreover, the remaining core glycan allows further derivatization such as glycan remodeling and dual conjugation. Practical and robust, our method generates conjugates in near quantitative yields, and both enzymes are commercially available.

4 April 2019 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
KMKevin R. Moulton
Kevin R. Moulton
ASAmissi Sadiki
Amissi Sadiki
BKBilyana N. Koleva
Bilyana N. Koleva
LOLincoln J. Ombelets
Lincoln J. Ombelets
TTTina H. Tran
Tina H. Tran
ZZZhaohui Sunny Zhou
Zhaohui Sunny Zhou